Nephrogenic systemic fibrosis: UK survey of the use of gadolinium-based contrast media

Clinical Radiology

Volumn 65, Issue 8, 2010, Pages 636-641

  Rees, O ^a   Agarwal, S K ^a  

^a WREXHAM MAELOR HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CONTRAST MEDIUM; GADOBENATE DIMEGLUMINE; GADOBUTROL; GADODIAMIDE; GADOFOSVESET; GADOLINIUM PENTETATE; GADOLINIUM PENTETATE MEGLUMINE; GADOTERATE MEGLUMINE; GADOTERIDOL; GADOVERSETAMIDE; DIAGNOSTIC AGENT; GADOLINIUM;

ARTICLE; AWARENESS; GLOMERULUS FILTRATION RATE; HEALTH CARE SURVEY; HIGH RISK BEHAVIOR; HUMAN; KIDNEY FUNCTION; MEDICAL SOCIETY; NEPHROGENIC SYSTEMIC FIBROSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; UNITED KINGDOM; CHEMICALLY INDUCED DISORDER; FEMALE; KIDNEY DISEASE; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; METHODOLOGY; PATHOPHYSIOLOGY; PROGNOSIS; PUBLIC HEALTH; QUESTIONNAIRE; RISK ASSESSMENT; STANDARD;

CONTRAST MEDIA; FEMALE; GADOLINIUM; GLOMERULAR FILTRATION RATE; GREAT BRITAIN; GUIDELINE ADHERENCE; HUMANS; KIDNEY DISEASES; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; NATIONAL HEALTH PROGRAMS; NEPHROGENIC FIBROSING DERMOPATHY; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS; QUESTIONNAIRES; RISK ASSESSMENT;

EID: 78149242704     PISSN: 00099260     EISSN: 1365229X     Source Type: Journal    
DOI: 10.1016/j.crad.2010.04.012     Document Type: Article

References (20)

1. Thomsen HS, Marckmann P, Logager CB. Nephrogenic systemic fibrosis (NSF): a late adverse reaction to some of the gadolinium based contrast agents. Cancer Imaging 2007;56:3433e41.
2. Grobner T. Gadoliniumda specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 2006;21:1104e8.
3. Marckmann P, Skov L, Rossen K, et al. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 2006;17:2359e62.
4. Broome DR, Girguis MS, Baron PW, et al. Gadodiamide-associated nephrogenic systemic fibrosisdwhy radiologists should be concerned. AJR Am J Roentgenol 2007;188:586e92.
5. Sadowski EA, Bennett LK, Chan MR, et al. Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology 2007;243:148e57.
6. Collidge TA, Thomson PC, Mark PB, et al. Gadolinium-enhanced MR imaging and nephrogenic systemic fibrosis: retrospective study of a renal replacement therapy cohort. Radiology 2007;245:168e75.
7. Todd DJ, Kagan A, Chibnik LB, et al. Cutaneous changes of nephrogenic systemic fibrosis. Predictor of early mortality and association with gadolinium exposure. Arthritis Rheum 2007;56:3433e41.
8. Deo A, Fogel M, Cowper SE. Nephrogenic systemic fibrosis: a population study examining the relationship of disease development to gadolinium exposure. Clin J Am Soc Nephrol 2007;2:264e7.
9. Othersen JB, Maize JC, Woolson RF. Nephrogenic systemic fibrosis after exposure to gadolinium in patients with renal failure. Nephrol Dial Transplant 2007;22:3179e85.
10. Perez-Rodriguez J, Lai S, Ehst BD, et al. Nephrogenic systemic fibrosis: incidence, associations, and effect of risk factor assessmentdreport of 33 cases. Radiology 2009;250:371e7.
11. Agarwal R, Brunelli SM, Williams K. Gadolinium-based contrast agents and nephrogenic systemic fibrosis: a systematic review and metaanalysis. Nephrol Dial Transplant 2009;24:856e63.
12. Thomsen HS. Nephrogenic systemic fibrosis: history and epidemiology. Radiol Clin N Am 2009;47:827e31.
13. European Society of Urogenital Radiology. ESUR guideline: gadolinium based contrast media and nephrogenic systemic fibrosis. Available at: http://www.esur.org/Nephrogenic-Fibrosis.39.0.html; [Last accessed date: 14.04.2009].
14. ThomsenHS.Howtoavoidnephrogenic systemicfibrosis: current guidelines in Europe and the United States. Radiol Clin N Am 2009;47:871e5.
15. Morcos SK. Nephrogenic systemic fibrosis following the administration of extracellular gadolinium based contrast agents: is the stability of the contrast agent molecule an important factor in the pathogenesis of this condition? Br J Radiol 2007;80:73e6.
16. Idée J, Port M, Dencausse A. Involvement of gadolinium chelates in the mechanism of nephrogenic systemic fibrosis: an update. Radiol Clin N Am 2009;47:855e69.
17. Thomsen HS, Marckmann P, Logager VB. Enhanced computed tomography or magnetic resonance imaging: a choice between contrast medium-induced nephropathy and nephrogenic systemic fibrosis? Acta Radiol 2007;48:593e6.
18. Bryant BJ, Im k, Broome DR. Evaluation of the incidence of nephrogenic systemic fibrosis in patients with moderate renal insufficiency administered gadobentate dimeglumine for MRI. Clin Radiol 2009;64:706e13.
19. Chrysochou C, Buckley DL, Dark P. Gadolinium-enhanced magnetic resonance imaging for renovascular disease and nephrogenic systemic fibrosis: critical review of the literature and UK experience. J Magn Reson Imaging 2009;29:887e94.
20. Penfield JG. Nephrogenic systemic fibrosis and the use of gadolinium based contrast agents. Pediatr Nephrol 2008;23:2121e9.